Strattera

(Atomoxetine)

ApprovedSmall molecule

Atomoxetine is used to treat attention-deficit/hyperactivity disorder (ADHD) by helping improve focus, attention, and impulse control in children and adults.[2] Strattera is currently approved and in use across 35 indications[4].[1]

Strattera is one of 715 small molecule programs targeting Enuresis. It is currently in Approved.

Indications

128

Total Trials

Active Trials

714

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

EnuresisActive, not recruiting

Methamphetamine DependenceActive, not recruiting

Nicotine DependenceApproved

Eating DisorderActive, not recruiting

Cognitive ImpairmentActive, not recruiting

Attention Deficit Hyperactivity DisorderActive, not recruiting

StrokeActive, not recruiting

Orthostatic IntoleranceActive, not recruiting

Orthostatic HypotensionActive, not recruiting

Parkinson DiseaseApproved

EnuresisPhase 1

Active, not recruiting

Methamphetamine DependencePhase 1

Active, not recruiting

Nicotine DependenceApproved

Approved

Eating DisorderApproved

Active, not recruiting

Cognitive ImpairmentPhase 2

Active, not recruiting

Attention Deficit Hyperactivity DisorderApproved

Active, not recruiting

StrokePhase 2

Active, not recruiting

Orthostatic IntolerancePhase 1

Active, not recruiting

Orthostatic HypotensionPhase 1

Active, not recruiting

Parkinson DiseaseApproved

Approved

Showing 10 of 35 indications

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Strattera

MMap77

Approved

6 2

Celexa

AbbVie

Preclinical

4 3

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 4

Zocor

OOrganon and Co

Preclinical

6 5

Ibrance

Pfizer

Preclinical

—6

Comtan

Orion Corporation, Orion Pharma

Preclinical

1 7

Catapres

Boehringer Ingelheim

Preclinical

1 8

Vivarin

HHikma Pharmaceuticals LLC

Preclinical

1 9

Compazine

GGlaxo Dba Glaxosmithkline

Preclinical

1 10

Luvox

SSolvay Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Obstructive Sleep Apnea

NCT05350215

Q4 2027

N/ARecruiting

Elective

NCT07239791

Phase 3Recruiting

Parkinson's Disease

NCT07316296

Q3 2028

Phase 2Not yet recruiting

Obesity

NCT06899178

Q3 2029

ApprovedRecruiting

Posttraumatic Stress Disorder With Attention Defic

NCT06573970

Clinical

Trials by Indication[1]

Attention Deficit Hyperactivity Disorder26 trials

Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder

Completed·NNew York State Psychiatric Institute·Phase 2·NCT00142961·2 enrolled

Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00962104·391 enrolled

Unknown status·FFar Eastern Memorial Hospital··NCT01130467·150 enrolled

Show 23 more trials

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed·AAbbott·Phase 2·NCT00429091·243 enrolled

Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00320528·269 enrolled

A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00447278·399 enrolled

The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder

Completed· Otsuka logo

Otsuka·Phase 2·NCT03324581·239 enrolled

Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children

Completed·UUniversity of Nebraska·Phase 4·NCT00254462·93 enrolled

Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Completed·NNew York State Psychiatric Institute·Phase 2·NCT00218543·20 enrolled

Driving in Adults With Attention-deficit/Hyperactivity Disorder (ADHD) Before and During Treatment With Atomoxetine

Completed·—·Phase 4·NCT00938743·50 enrolled

A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents

Terminated· Eli Lilly logo

Eli Lilly·Phase 4·NCT01127646·23 enrolled

Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE

Terminated· Eli Lilly logo

Eli Lilly·Phase 4·NCT00687609·7 enrolled

A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed· AbbVie logo

AbbVie·Phase 2·NCT00528697·278 enrolled

Concerta and Strattera on the Executive Function in Attention Deficit Hyperactivity Disorder (ADHD) Children

Completed·PPeking University·Phase 4·NCT01065259·262 enrolled

Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00636818·45 enrolled

An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00191737·147 enrolled

Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder

Completed·—·N/A·NCT00399763·70 enrolled

Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children

Completed·IIcahn School of Medicine at Mount Sinai·Phase 4·NCT00183391·232 enrolled

An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00191516·257 enrolled

Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00546910·125 enrolled

A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00969618·211 enrolled

Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.

Withdrawn· Pfizer logo

Pfizer·Phase 2·NCT00562055

A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00471354·228 enrolled

Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00386581·105 enrolled

Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD)

Unknown status·PPeking University·Phase 4·NCT01339286·100 enrolled

Attention-deficit/Hyperactivity Disorder Translational Center for Identifying Biomarkers

Unknown status·—·Phase 4·NCT02623114·400 enrolled

Adolescent8 trials

Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD

Withdrawn·MMassachusetts General Hospital·Phase 4·NCT01207622

Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00191542·100 enrolled

Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00607919·209 enrolled

Show 5 more trials

Enhancing the Effects of Adolescent Alcohol Treatment With Atomoxetine

Completed·—·Phase 2·NCT04565288·42 enrolled

Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00191048·105 enrolled

Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00191035·520 enrolled

Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00406354·181 enrolled

Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD)

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00760747·112 enrolled

Treatment7 trials

Atomoxetine Treatment for ADHD and Marijuana Dependence

Completed·MMedical University of South Carolina·Phase 2·NCT00360269·38 enrolled

Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar

Completed· Pfizer logo

Pfizer·Phase 2·NCT00174226·241 enrolled

Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)

Completed·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT03091400·11 enrolled

Show 4 more trials

Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy

Completed·MMassachusetts General Hospital·Phase 4·NCT00181948·30 enrolled

Concerta Treatment in Adults With ADHD NOS

Completed·MMassachusetts General Hospital·Phase 4·NCT00181740·30 enrolled

Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 4·NCT03781765·44 enrolled

Effects of Atomoxetine Treatment in Humans

Completed·YYale University·Phase 1/2·NCT00611936·10 enrolled

Schizophrenia6 trials

A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT00089869

Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT00628394·119 enrolled

Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia

Completed·UUniversity of Maryland, Baltimore·N/A·NCT00161031·30 enrolled

Show 3 more trials

Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia

Completed·RResearch Foundation for Mental Hygiene, Inc.·Phase 4·NCT00488163·20 enrolled

Effects of Atomoxetine on Cognitive Function in Schizophrenia

Completed·YYale University·Phase 2·NCT00420498·12 enrolled

A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia

Completed·UUniversity of Pittsburgh·Phase 4·NCT00222794·66 enrolled

Attention6 trials

Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00716274·110 enrolled

Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00191880·100 enrolled

Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy

Unknown status·UUniversity of Cincinnati·Phase 3·NCT01330693·120 enrolled

Show 3 more trials

Interventions for Children With Attention and Reading Disorders

Completed·TThe University of Texas Health Science Center, Houston·Phase 4·NCT01133847·222 enrolled

Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00530335·45 enrolled

Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)

Completed· Eli Lilly logo

Eli Lilly·Phase 2/3·NCT00191295·240 enrolled

58 more indications

Children5 trials

Role of Coenzyme Q in ADHD in Children

Recruiting·SSherief Abd-Elsalam·Phase 3·NCT04216186·40 enrolled

Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD

Completed·UUniversity of Oklahoma·Phase 3·NCT00418262·27 enrolled

EAA/Therapy for Treating Children With ADHD

Unknown status·SSamsung Medical Center·N/A·NCT02482649·46 enrolled

Show 2 more trials

Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD

Completed·SState University of New York at Buffalo·Phase 4·NCT00918567·56 enrolled

The Neuroprotective Effects of Methylphenidate and Atomoxetine in Children With ADHD: A Lipidomic Study

Completed·NNational Taiwan University Hospital·N/A·NCT03936491·105 enrolled

Obstructive Sleep Apnea4 trials

Crossover Trial of AD109 in Obstructive Sleep Apnea

Completed·AApnimed·Phase 2·NCT04580394·60 enrolled

Crossover Trial of AD036 in Obstructive Sleep Apnea

Completed·AApnimed·Phase 2·NCT04445688·62 enrolled

Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea

Completed·—·Phase 1/2·NCT05944965·27 enrolled

Show 1 more trial

Effect of Atomoxetine and DAW2022 on OSA Severity

Recruiting·BBrigham and Women's Hospital·Preclinical·NCT05350215·18 enrolled

Parkinson's Disease3 trials

Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach

Recruiting·RRadboud University Medical Center·Phase 3·NCT07316296·60 enrolled

TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease

Completed·HHubert Fernandez·Phase 1·NCT02879136·23 enrolled

Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease

Completed·UUniversity of Pennsylvania·Phase 4·NCT00304161·55 enrolled

Humans2 trials

Cognitive Effects of Atomoxetine in Humans: Genetic Moderators

Completed·YYale University·N/A·NCT01498549·35 enrolled

Atomoxetine Effects in Humans

Completed·YYale University·Phase 1/2·NCT00607568·10 enrolled

ADHD2 trials

Black Seed Oil in ADHD

Not yet recruiting·—·Phase 2·NCT06542887·60 enrolled

Network Connectivity and Inhibitory Control Under Atomoxetin Challenge- A Pharmacological 'Resting State' and 'Inhibiton Task' Study in Patients With ADHD

Completed·RRWTH Aachen University·Phase 4·NCT03661788·38 enrolled

Cognitive impairment2 trials

Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)

Completed·MMedical University of South Carolina·Phase 2·NCT01738191·30 enrolled

Effects of Atomoxetine in Mild Cognitive Impairment

Completed·EEmory University·Phase 2·NCT01522404·39 enrolled

Autism2 trials

Atomoxetine, Placebo and Parent Management Training in Autism

Completed·UUniversity of Rochester·Phase 4·NCT00844753·128 enrolled

Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism

Completed·MMassachusetts General Hospital·Phase 3·NCT00498173·60 enrolled

Insomnia2 trials

Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents

Unknown status·RRhode Island Hospital·Phase 4·NCT00252278·36 enrolled

The Effect of a Once Daily Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents

Completed·RRhode Island Hospital·Phase 4·NCT00566371·36 enrolled

Sleep Apnea2 trials

Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy

Unknown status·—·Phase 1/2·NCT05550246·22 enrolled

A Novel Pharmacological Therapy for Obstructive Sleep Apnea

Completed·BBrigham and Women's Hospital·Phase 2·NCT03919955·117 enrolled

Orthostatic Intolerance2 trials

Treatment of Orthostatic Intolerance

Active, not recruiting·SSatish R. Raj·Phase 1/2·NCT00262470·150 enrolled

Orthostatic Intolerance After Bariatric Surgery

Terminated·VVanderbilt University Medical Center·Phase 1·NCT03808740·10 enrolled

Cannabis Dependence1 trial

Atomoxetine for the Treatment of Cannabis Dependence

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT00167297·16 enrolled

Menopausal Women1 trial

Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women

Completed·UUniversity of Pennsylvania·N/A·NCT00611533·16 enrolled

Opioid Dependence1 trial

Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia

Completed·YYale University·Phase 2·NCT01863251·90 enrolled

Drug Monitoring1 trial

Therapeutic Drug Monitoring in Child and Adolescent Psychiatry

Completed·MMedical University of Vienna··NCT01057329·200 enrolled

Substance Abuse1 trial

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT04132557·430,000 enrolled

Stroke1 trial

Post-stroke Neural Plasticity With Atomoxetine

Completed·LLumy Sawaki·Phase 2·NCT02788357·12 enrolled

Chronic1 trial

Unraveling the Nature of Impaired Pain Inhibition in Patients With Chronic Whiplash-associated Disorders

Completed·VVrije Universiteit Brussel··NCT01601912·59 enrolled

Social Anxiety Disorder1 trial

Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder

Completed·UUniversity of California, San Diego·Phase 2/3·NCT00260533·27 enrolled

Substance Use Disorder (SUD)1 trial

Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility

Completed·NNYU Langone Health·N/A·NCT00953862·18 enrolled

Huntington's Disease1 trial

Atomoxetine and Huntington's Disease

Completed·UUniversity of Iowa·Phase 2·NCT00368849·20 enrolled

Attention Deficit Hyperactivity Disorder (ADHD)1 trial

A Study to Examine the Progression of Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment and to Analyze Associated Factors

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT01624649·289 enrolled

Orthostatic Hypotension1 trial

Treatment of Orthostatic Hypotension in Autonomic Failure

Completed·VVanderbilt University·Phase 1·NCT00223691·389 enrolled

Eating Disorder1 trial

Atomoxetine in the Treatment of Binge Eating Disorder

Completed·LLindner Center of HOPE·Phase 4·NCT00327834

Brain Injury1 trial

Efficacy Study of Strattera for Treating Attention Disorders in Traumatic Brain Injury (TBI)

Completed·—·N/A·NCT00702364·60 enrolled

Neuroimaging1 trial

Identification of Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of ADHD

Unknown status·—··NCT02430896·600 enrolled

Executive Function1 trial

Effects of Atx and Oros-mph on Executive Functions

Completed·TTC Erciyes University·Phase 4·NCT02352051·43 enrolled

Cognition1 trial

The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype

Terminated·NNational Institute of Mental Health (NIMH)·Phase 2·NCT00548327·11 enrolled

Stress Response1 trial

Atomoxetine's Effects On Nicotine Response And Stress Response In Smokers

Withdrawn·YYale University·Phase 1/2·NCT02046551

TED1 trial

Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline

Completed·UUniversity of Turku·Phase 1·NCT01794975·8 enrolled

Medication1 trial

A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT04113551·17,418 enrolled

Substance Use Disorder1 trial

Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD

Completed·UUniversity of Pittsburgh·Phase 2·NCT00029614·24 enrolled

Vasovagal syncope1 trial

Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope

Completed·UUniversity of Calgary·Phase 2·NCT02500732·57 enrolled

Elective1 trial

Role of the Noradrenergic System in the Regulation of Learning Dynamics: Evaluation of the Effect of a Low-dose Selective Noradrenaline Reuptake Inhibitor (NOISYXETINE)

Recruiting·—·N/A·NCT07239791·160 enrolled

Outcome1 trial

Safety Study of Atomoxetine and Cerebrovascular Outcomes

Completed· Eli Lilly logo

Eli Lilly··NCT00634439·72,000 enrolled

Enuresis1 trial

Evaluating the Efficacy of Atomoxetine in Reducing Primary Nocturnal Enuresis in Children With ADHD: A Randomized, Placebo-Controlled Study

Not yet recruiting·TTanta University·Phase 1·NCT06841666·100 enrolled

Methamphetamine Dependence1 trial

Clinical Efficacy of Atomoxetine for Methamphetamine Dependence

Completed·UUniversity of Arkansas·Phase 1/2·NCT01557569·20 enrolled

Hypoglycemia1 trial

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine

Completed·UUniversity of Maryland, Baltimore·Phase 1·NCT00780650·56 enrolled

Executive Dysfunction1 trial

Treatment of Executive Dysfunction in Parkinson's Disease

Completed·JJohns Hopkins University·N/A·NCT00286949·12 enrolled

Cocaine Dependence1 trial

Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial

Completed·SSharon Walsh·Phase 2·NCT00617201·50 enrolled

Functional Outcomes1 trial

Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00191633·200 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH

Completed·SSeoul National University Hospital·Phase 4·NCT03350659·50 enrolled

Bariatric Surgery1 trial

Bariatric Surgery and Pharmacokinetics of Atomoxetine

Completed·NNorwegian University of Science and Technology··NCT03460210·12 enrolled

Efficacy1 trial

Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects

Withdrawn·TTemple University·Phase 3·NCT00255138

Treatment Compliance1 trial

Treatment Compliance in Children and Adolescents on ADHD Medication

Completed· Eli Lilly logo

Eli Lilly··NCT00540826·518 enrolled

Autonomic Failure1 trial

Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)

Completed·VVanderbilt University Medical Center·Phase 2·NCT02784535·48 enrolled

Chemotherapy1 trial

Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL

Terminated·MMonarch Medical Research·Phase 4·NCT00299234·1 enrolled

Obesity1 trial

Atomoxetine in Melanocortin Obesity Syndrome

Not yet recruiting·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT06899178·20 enrolled

Veterans1 trial

Atomoxetine in Veterans With Comorbid ADHD/PTSD

Completed·VVA Office of Research and Development·Phase 4·NCT02287038·44 enrolled

Alcohol1 trial

A Dose Response Effect of Atomoxetine to the Acute Effects of Alcohol

Terminated·UUniversity of Colorado, Boulder·Phase 1·NCT01408589·86 enrolled

Hypertension1 trial

Trial of AD113 and Atomoxetine in OSA Patients With Hypertension

Completed·AApnimed·Phase 2·NCT04905979·21 enrolled

Alcohol Abuse1 trial

Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00190957·140 enrolled

PET1 trial

Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline

Completed·UUniversity of Turku·Phase 1·NCT01435213·10 enrolled

Tourette's Syndrome1 trial

Atomoxetine in Patients With Tourette's Syndrome

Terminated·PPoitiers University Hospital·Phase 2·NCT04354103·5 enrolled

Interaction1 trial

Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine - 1

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 1·NCT00265265·16 enrolled

ESS1 trial

Safety Study to Assess Atomoxetine With MA Abusers and Healthy Controls

Completed·UUniversity of California, Los Angeles·Phase 1·NCT02014064·41 enrolled

Autism Spectrum Disorder1 trial

Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00380692·97 enrolled

Posttraumatic Stress Disorder With Attention Defic1 trial

Atomoxetine Effect on Attention, Executive Function, and Quality of Life in Veterans With Posttraumatic Stress Disorder

Recruiting·VVA Office of Research and Development·Approved·NCT06573970·160 enrolled

Unspecified2 trials

A Bioequivalence (BE) Study in Healthy Subjects

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01177943·42 enrolled

Long-Term, Open Label Atomoxetine Study

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00190684·1,553 enrolled

Regulatory

FDA Approval Timeline[5]

Nov 26, 2002

STRATTERA

NDA NDA021411

Mar 20, 2026

ATONCY

NDA NDA220320

Sources

References

[1]
ClinicalTrials.gov — 128 trial records for Atomoxetine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Strattera drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Atomoxetine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Atomoxetine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA220320). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Map77 company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Norepinephrine Transporter Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: MMap77

Strattera

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q3 2028

Q3 2029

Trials by Indication[1]

Attention Deficit Hyperactivity Disorder26 trials

Adolescent8 trials

Treatment7 trials

Schizophrenia6 trials

Attention6 trials

Children5 trials

Obstructive Sleep Apnea4 trials

Parkinson's Disease3 trials

Humans2 trials

ADHD2 trials

Cognitive impairment2 trials

Autism2 trials

Insomnia2 trials

Sleep Apnea2 trials

Orthostatic Intolerance2 trials

Cannabis Dependence1 trial

Menopausal Women1 trial

Opioid Dependence1 trial

Drug Monitoring1 trial

Substance Abuse1 trial

Stroke1 trial

Chronic1 trial

Social Anxiety Disorder1 trial

Substance Use Disorder (SUD)1 trial

Huntington's Disease1 trial

Attention Deficit Hyperactivity Disorder (ADHD)1 trial

Orthostatic Hypotension1 trial

Eating Disorder1 trial

Brain Injury1 trial

Neuroimaging1 trial

Executive Function1 trial

Cognition1 trial

Stress Response1 trial

TED1 trial

Medication1 trial

Substance Use Disorder1 trial

Vasovagal syncope1 trial

Elective1 trial

Outcome1 trial

Enuresis1 trial

Methamphetamine Dependence1 trial

Hypoglycemia1 trial

Executive Dysfunction1 trial

Cocaine Dependence1 trial

Functional Outcomes1 trial

Efficacy and Safety1 trial

Bariatric Surgery1 trial

Efficacy1 trial

Treatment Compliance1 trial

Autonomic Failure1 trial

Chemotherapy1 trial

Obesity1 trial

Veterans1 trial

Alcohol1 trial

Hypertension1 trial

Alcohol Abuse1 trial

PET1 trial

Tourette's Syndrome1 trial

Interaction1 trial

ESS1 trial

Autism Spectrum Disorder1 trial

Posttraumatic Stress Disorder With Attention Defic1 trial

Unspecified2 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News